Immunitybio Inc (IBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Immunitybio Inc (IBRX) Competitors
The companies most similar to Immunitybio are Immunovant (IMVT), Iovance Biotherapeutics (IOVA) and Abivax SA American Depositary Shares (ABVX). By market cap, Immunitybio ranks 8th of the 13 companies on this page; Vaxcyte (PCVX) is the largest at $10.03B.
Peer Comparison
IBRX's ROIC of -780.5% is below the peer median of -43.4%, and its revenue growth of 52.3% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Immunitybio (IBRX) | $6.40B | N/A | 30.3x | 0.0% | -780.5% | 52.3% | 0.00% |
| Immunovant Inc (IMVT) | $7.07B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| Abivax SA American Depositary Shares (ABVX) | $7.67B | N/A | N/A | 0.0% | -159.6% | -6.8% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Vaxcyte Inc (PCVX) | $10.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CG Oncology, Inc. Common stock (CGON) | $6.65B | N/A | N/A | 0.0% | -21.1% | -3.7% | 0.00% |
| Cytokinetics Inc (CYTK) | $7.82B | N/A | 65.3x | 0.0% | -66.0% | 2357.0% | 0.00% |
| Spyre Therapeutics Inc. (SYRE) | $9.88B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| Dianthus Therapeutics Inc. (DNTH) | $5.17B | N/A | N/A | 0.0% | N/A | 205.6% | 0.00% |
| Tango Therapeutics Inc (TNGX) | $4.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Peer median | $6.86B | 176.8x | 10.1x | 0.0% | -43.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Immunitybio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immunovant Inc (IMVT) | Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. | IMVT competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| Abivax SA American Depositary Shares (ABVX) | Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. | ABVX competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Vaxcyte Inc (PCVX) | Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. | PCVX competitors |
| CG Oncology, Inc. Common stock (CGON) | CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070... | CGON competitors |
| Cytokinetics Inc (CYTK) | Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering... | CYTK competitors |
| Spyre Therapeutics Inc. (SYRE) | Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by... | SYRE competitors |
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| Dianthus Therapeutics Inc. (DNTH) | Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops... | DNTH competitors |
| Tango Therapeutics Inc (TNGX) | Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation... | TNGX competitors |
Frequently Asked Questions About IBRX
Who are Immunitybio's main competitors?
The companies most similar to Immunitybio include Immunovant (IMVT), Iovance Biotherapeutics (IOVA), Abivax SA American Depositary Shares (ABVX), TG Therapeutics (TGTX) and Legend Biotech (LEGN), listed from the closest match.
Who is Immunitybio's biggest competitor?
Vaxcyte (PCVX) is the largest of the similar companies at $10.03B; Immunovant (IMVT) is the closest match by business profile, size, sector and industry.
How does IBRX stock compare with its competitors?
IBRX's P/S is 30.3x against a peer median of 10.1x; its net margin is 0.0% against a peer median of 0.0%.
Which of Immunitybio's competitors pays a higher dividend?
Immunitybio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Immunitybio bigger than its competitors?
No. Immunitybio is 8th by market cap among the 13 companies on this page; the largest is Vaxcyte (PCVX) at $10.03B.
IBRX pages: Overview, Earnings, Forecast, Financials, Competitors